Brief: Metacrine Reports Topline Results For Phase 2A Combination Trial For Type 2 Diabetes And NASH Treatment
02/11/2021 13:11
Nov 2 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE REPORTS TOPLINE RESULTS FOR MET409 PHASE 2A
COMBINATION TRIAL IN PATIENTS WITH TYPE 2 DIABETES AND NASH
* METACRINE, INC. - ALL TRIAL REGIMENS HAD FAVORABLE SAFETY
PROFILES AND WERE GENERALLY WELL-TOLERATED, WITH NO
TREATMENT-RELATED SERIOUS ADVERSE EVENT
Source text for Eikon: ID:nGNX3R2vQG
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions